December 19, 2016 — BioTrace Medical Inc. announced the first commercial use of the company’s Tempo Temporary Pacing Lead since U.S. Food and Drug Administration (FDA) 510(k) clearance in October.

Advances in Nuclear Cardiology and Cardiac CT

December 13, 2016 — Coupling data mining of adverse event reports and electronic health records with targeted laboratory experiments, researchers found a way to identify and confirm previously unknown drug interactions, according to a new study. The study was published in October in the Journal of the American College of Cardiology.

Drug-drug interactions account for a significant proportion of side effects and hospitalizations, but they are often very difficult to predict.

Lombard Medical Inc. announced that its Altura endovascular stent graft system was featured in a scientific presentation at the 43rd annual VEITHsymposium, Nov. 15-19 in New York City.  The Altura stent graft, which was launched commercially in Europe earlier in 2016, is specifically designed to simplify treatment in patients with normal abdominal aortic aneurysm (AAA) anatomy.

Biotronik announced the presentation of data confirming the efficacy of the Pulsar-18 bare metal self-expanding stent (BMS SE) at VEITHsymposium 2016, Nov. 15-19 in New York. Jos C. van den Berg, University of Bern, Switzerland, presented the encouraging interim results for Pulsar-18 in treatment of superficial femoral artery (SFA) disease during the symposium’s main program on behalf of lead investigator for the BIOFLEX PEACE all-comers trial, Michael Lichtenberg, Vascular Center, Arnsberg, Germany.

Scientists at Tokyo Institute of Technology have developed a portable and wearable terahertz scanning device for non-invasive inspection of three-dimensional objects. The device is made using arrays of carbon nanotubes and does not require bulky peripheral optical components.

The primary goal of any healthcare provider is to improve the lives of patients through effective treatment. However, because they are also businesses, hospitals have concerns that entail much more than this. To be viable in the long term, hospitals must manage their margins to fund their mission.

LimFlow SA announced in November that it received the CE Mark for its fully percutaneous LimFlow System designed for venous arterialization of the lower limbs in end-stage patients at risk of limb amputation for critical limb ischemia (CLI).

St. Jude Medical Inc. announced results of the MOMENTUM 3 U.S. IDE Clinical Study during a late-breaking clinical trial session at the American Heart Association (AHA) Scientific Sessions, Nov. 12-16 in New Orleans. The MOMENTUM 3 study compared the HeartMate 3 Left Ventricular Assist System (LVAS) to the HeartMate II LVAS in treating advanced stage heart failure, and is the largest LVAD trial in the world to evaluate both short-term and long-term patients in a single study. The study results demonstrated patients receiving the HeartMate 3 LVAS had an 86.2 percent survival rate with freedom from disabling stroke and reoperation to repair or replace the device.

Corsens Medical Ltd. announced that it has received clearance for a Pre-Marketing Notification (510(k)) with the U.S. Food and Drug Administration (FDA) for its Corsens Cardiac Monitor (patents pending).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now